Cargando…
Prediction of near‐future glycated hemoglobin levels using glycated albumin levels before and after treatment for diabetes
Aims/Introduction: In the present study, whether near‐future glycated hemoglobin (A1C) levels could be predicted by changes in glycated albumin (GA) levels before and after treatment for diabetes was investigated. Materials and Methods: After starting diabetes treatment, GA and A1C levels are assu...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014972/ https://www.ncbi.nlm.nih.gov/pubmed/24843503 http://dx.doi.org/10.1111/j.2040-1124.2011.00107.x |
Sumario: | Aims/Introduction: In the present study, whether near‐future glycated hemoglobin (A1C) levels could be predicted by changes in glycated albumin (GA) levels before and after treatment for diabetes was investigated. Materials and Methods: After starting diabetes treatment, GA and A1C levels are assumed to change exponentially. From this assumption, the equation for predicting near‐future GA and A1C levels was derived. A total of 54 patients with type 2 diabetes mellitus in whom diabetes treatment was initiated or altered were enrolled. By incorporating GA and A1C values before and 2–4 weeks after starting treatment (second visit) into the equation, the predicted GA and A1C levels at the third visit (5–7 weeks after treatment) were obtained. Results: A strong and positive correlation was observed between predicted GA and measured GA at the third visit (R = 0.669, P < 0.0001). Similarly, a strong and positive correlation was observed between the predicted A1C and the measured A1C at the third visit (R = 0.795, P < 0.0001). Conclusions: GA and A1C levels 1–3 months after starting diabetes treatment could be predicted using the equation developed. The prediction of near‐future A1C levels using GA levels at two points would be useful for judging the effectiveness of ongoing diabetes treatment at an earlier stage. (J Diabetes Invest, doi: 10.1111/j.2040‐1124.2011.00107.x, 2011) |
---|